BMRN Biomarin Pharmaceutical Inc
Price (delayed)
$63.3
Market cap
$12.08B
P/E Ratio
28.13
Dividend/share
N/A
EPS
$2.25
Enterprise value
$11.73B
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and
Highlights
The net income has surged by 155% year-on-year and by 32% since the previous quarter
Biomarin Pharmaceutical's EPS has surged by 153% YoY and by 32% QoQ
Key stats
What are the main financial stats of BMRN
Market
Valuations
Earnings
Shares outstanding
190.78M
Market cap
$12.08B
Enterprise value
$11.73B
Price to earnings (P/E)
28.13
Price to book (P/B)
2.13
Price to sales (P/S)
4.21
EV/EBIT
21.15
EV/EBITDA
18.02
EV/Sales
4.11
Revenue
$2.85B
Gross profit
$2.27B
Operating income
$484.21M
Net income
$426.86M
EBIT
$554.43M
EBITDA
$650.86M
Free cash flow
$497.42M
Per share
Balance sheet
Liquidity
EPS
$2.25
EPS diluted
$2.21
Free cash flow per share
$2.62
Book value per share
$29.69
Revenue per share
$15.02
TBVPS
$34.4
Total assets
$6.99B
Total liabilities
$1.33B
Debt
$595.14M
Equity
$5.66B
Working capital
$2.63B
Debt to equity
0.11
Current ratio
5.33
Quick ratio
2.96
Net debt/EBITDA
-0.53
Margins
Efficiency
Dividend
EBITDA margin
22.8%
Gross margin
79.7%
Net margin
15%
Operating margin
17%
Return on assets
6.1%
Return on equity
8%
Return on invested capital
9.9%
Return on capital employed
8.7%
Return on sales
19.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BMRN stock price
How has the Biomarin Pharmaceutical stock price performed over time
Intraday
0.89%
1 week
6.98%
1 month
-11.51%
1 year
-22.96%
YTD
-3.7%
QTD
-10.45%
Financial performance
How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$2.85B
Gross profit
$2.27B
Operating income
$484.21M
Net income
$426.86M
Gross margin
79.7%
Net margin
15%
The operating income has surged by 161% year-on-year and by 38% since the previous quarter
The net income has surged by 155% year-on-year and by 32% since the previous quarter
Biomarin Pharmaceutical's operating margin has soared by 121% YoY and by 34% from the previous quarter
The net margin has soared by 117% year-on-year and by 28% since the previous quarter
Growth
What is Biomarin Pharmaceutical's growth rate over time
Valuation
What is Biomarin Pharmaceutical stock price valuation
P/E
28.13
P/B
2.13
P/S
4.21
EV/EBIT
21.15
EV/EBITDA
18.02
EV/Sales
4.11
Biomarin Pharmaceutical's EPS has surged by 153% YoY and by 32% QoQ
BMRN's P/E is 85% below its 5-year quarterly average of 187.7 and 47% below its last 4 quarters average of 52.9
The stock's price to book (P/B) is 41% less than its 5-year quarterly average of 3.6 and 21% less than its last 4 quarters average of 2.7
The equity has grown by 14% YoY and by 4.5% from the previous quarter
BMRN's price to sales (P/S) is 45% less than its 5-year quarterly average of 7.6 and 23% less than its last 4 quarters average of 5.5
The revenue has grown by 18% YoY and by 3.7% from the previous quarter
Efficiency
How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has soared by 175% YoY and by 36% from the previous quarter
BMRN's return on assets has surged by 144% year-on-year and by 30% since the previous quarter
The ROE has soared by 129% YoY and by 29% from the previous quarter
Biomarin Pharmaceutical's return on sales has surged by 128% YoY and by 31% QoQ
Dividends
What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BMRN.
Financial health
How did Biomarin Pharmaceutical financials performed over time
The company's current ratio has surged by 112% YoY and by 25% QoQ
BMRN's quick ratio has surged by 104% year-on-year and by 24% since the previous quarter
The debt is 89% smaller than the equity
BMRN's debt to equity has dropped by 50% year-on-year
The debt is down by 45% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.